MetaVia's DA-1726 shows promising Phase 1 results at EASL 2026, achieving significant weight loss and liver improvement signs in obesity treatment.

MetaVia Inc. has successfully concluded dose titration in its Phase 1 trial evaluating DA-1726 for obesity, marking a significant milestone in treatment development.

MetaVia Inc. will present groundbreaking therapies for obesity and metabolic diseases at a virtual investor forum on June 24, 2026. Join live for insights!

Using AI to find stock market opportunities.

Obesity Update: Wegovy’s 7.2mg Bid, Rhythm’s Oral Win, TRPV1 Breakthrough & More In this week’s Obesity Updates, we spotlight the […] The post Obesity Weekly News – July 15th 2025 appeared first on LucidQuest Ventures.

Click to view the official SEC document.

This biweekly Obesity video recap highlights regulatory approvals, lifecycle expansion, early-stage clinical progress, and evolving commercial strategies across cardiometabolic therapies. 🔬 Key Highlights: 🧭 Boehringer Ingelheim builds an obesity unit around survodutide 💉 Novo Nordisk launches higher-dose Wegovy HD 🛒 Eli Lilly expands Foundayo distribution through pharmacy and telehealth 🧪 MetaVia starts higher-dose Phase 1 dosing for DA-1726 🤝 JW Pharmaceutical licenses biweekly Bofanglutide in Korea 📊 ACC 2026 analysis backs CagriSema versus its components 💊 FDA clears Lilly’s Foundayo, an oral GLP-1 for weight loss ⚖️ Novo Nordisk presents ORION and OPTIC against orforglipron Chapters: 0:00 Introduction 0:07 Boehringer Ingelheim builds an obesity unit around survodutide 0:31 Novo Nordisk launches higher-dose Wegovy HD 0:51 Eli Lilly expands Foundayo distribution through pharmacy and telehealth 1:14 MetaVia starts higher-dose Phase 1 dosing for DA-1726 1:35 JW Pharmaceutical licenses biweekly Bofanglutide in Korea 1:54 ACC 2026 analysis backs CagriSema versus its components 2:16 FDA clears Lilly’s Foundayo, an oral GLP-1 for weight loss 2:32 Novo Nordisk presents ORION and OPTIC against orforglipron 2:50 How to reach us 📢 Stay Ahead in Obesity Research! ✅ Like, share, and subscribe for future updates on Obesity ✅ Visit www.lqventures.com for expert healthcare insights and consulting services. ✅ Contact LucidQuest at info@lqventures.com for strategic guidance on Obesity innovations and clinical research. 🔔 Turn on notifications so you never miss an update! #Obesity #FDA #GLP1 #ClinicalTrials #PharmaNews #Biotech #DrugDevelopment #LucidQuest

MetaVia Inc. unveils significant preclinical findings supporting DA-1726's potential for reducing waist circumference, a promising step in obesity treatment.

Reported Wednesday, Sep 9 - 8:03am EDT (TheFly subscription required to read more.)

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Click to view the official SEC document.

MetaVia (NASDAQ:MTVA – Get Free Report) announced its earnings results on Thursday. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.08), FiscalAI reports. MetaVia Trading Up 2.8% Shares of MetaVia stock traded up $0.04 on Friday, reaching $1.49. 107,022 shares of the company were exchanged, compared [...]

MetaVia Inc. shares impressive Q2 2026 financial results, highlighting advancements in obesity treatment and promising data from clinical trials.

DA-1726 showed up to 9.1% mean weight loss after eight weeks, while cash stood at $12.6M; MetaVia is working to schedule an FDA meeting.